Provided by Tiger Trade Technology Pte. Ltd.

Keros Therapeutics, Inc.

11.01
-0.5100-4.43%
Post-market: 11.010.00000.00%19:30 EDT
Volume:185.32K
Turnover:2.08M
Market Cap:218.30M
PE:-3.55
High:11.63
Open:11.56
Low:10.95
Close:11.52
52wk High:22.55
52wk Low:9.69
Shares:19.83M
Float Shares:18.25M
Volume Ratio:1.23
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1046
EPS(LYR):2.30
ROE:-17.16%
ROA:-11.78%
PB:0.83
PE(LYR):4.79

Loading ...

Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play

TIPRANKS
·
Oct 01

Keros Therapeutics Expects $20 Million Milestone Payment From Takeda

MT Newswires Live
·
Sep 29

Keros Therapeutics, - Expects $20 Mln Development Milestone Payment from Takeda for Elritercept

THOMSON REUTERS
·
Sep 29

Keros Therapeutics, - to Distribute 25% of Net Cash Proceeds from Milestone Payment to Stockholders

THOMSON REUTERS
·
Sep 29

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

THOMSON REUTERS
·
Sep 29

Keros Doses First Patient in Phase 2 Rinvatercept Trial for Duchenne Muscular Dystrophy

Reuters
·
Sep 28

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in Dmd

THOMSON REUTERS
·
Sep 28

Keros Therapeutics - May Offer up to $350 Mln of Securities - SEC Filing

THOMSON REUTERS
·
Sep 11

Keros Therapeutics Announces Share Repurchase Authorization Program

TIPRANKS
·
Sep 09

Keros Therapeutics announces $5M share repurchase program after Takeda payment

TIPRANKS
·
Sep 09

Keros Therapeutics Launches $5 Million Share Buyback Program

Reuters
·
Sep 09

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

THOMSON REUTERS
·
Sep 09

Wells Fargo Sticks to Their Buy Rating for Keros Therapeutics (KROS)

TIPRANKS
·
Sep 02

Keros Therapeutics Director Charles W. Newton Sells 551 Common Shares Worth $5,675.3

Reuters
·
Aug 21

Keros Therapeutics Director Jean Jacques Bieneaime Acquires USD 10,270 in Common Shares

Reuters
·
Aug 20

Keros Therapeutics Controller, VP Finance Annita Tanini Files Initial Beneficial Ownership Statement

Reuters
·
Aug 14

Keros Therapeutics (KROS) Receives a Hold from Bank of America Securities

TIPRANKS
·
Aug 11

Entrada Therapeutics Q2 Net Loss Narrows on Lower Costs

Reuters
·
Aug 05

Seres Therapeutics Q2 Net Income Turns Positive on VOWST Sale Gain

Reuters
·
Aug 05

Sweden's Xspray Posts Narrow Q2 Pretax Loss as Costs Fall

Reuters
·
Aug 05